	US 12,453,735 B2
	Treating cancer with a CCK receptor inhibitor and an immune checkpoint inhibitor
Jill P. Smith, Camp Hill, PA (US); Louis Weiner, Washington, DC (US); Sandra Jablonski, Silver Spring, MD (US); Sandeep Nadella, Alexandria, VA (US); and Shangzi Wang, Derwood, MD (US)
Assigned to GEORGETOWN UNIVERSITY, Washington, DC (US)
Filed by GEORGETOWN UNIVERSITY, Washington, DC (US)
Filed on Feb. 23, 2022, as Appl. No. 17/678,754.
Application 17/678,754 is a continuation of application No. 16/493,882, granted, now 11,278,551, previously published as PCT/US2018/022617, filed on Mar. 15, 2018.
Claims priority of provisional application 62/471,761, filed on Mar. 15, 2017.
Prior Publication US 2022/0257609 A1, Aug. 18, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5513 (2006.01); A61K 31/198 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC A61K 31/5513 (2013.01) [A61K 31/198 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01)]

6 Claims

1. A method for treating a cholecystokinin (CCK) receptor-expressing pancreatic tumor in a subject, comprising administering to the subject an effective amount of proglumide and an effective amount of gemcitabine, wherein the proglumide decreases fibrosis of the tumor.